Precise and Objective Identification of Bertolotti Syndrome Using Novel Kinematic Biomarkers
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Claudia Tellman
- Phone Number: 216-444-3026
- Email: tellmac@ccf.org
Study Contact Backup
- Name: Nya Robinson
- Phone Number: 216-445-1741
- Email: ROBINSN8@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Lower Back Pain Cohort
- Positive diagnosis of sacroiliac pain or lumbosacral facet arthritis pain
- Age ≥ 18 years
Bertolotti's Syndrome Cohort
- Positive diagnosis of Bertolotti's Syndrome
- Age ≥ 18 years
- Positive imaging for Bertolotti's Syndrome
- Previous analgesic injection results
Exclusion Criteria:
Lower Back Pain Cohort
- History of spinal deformity, previous spinal surgeries, spinal infections
- Pregnant women
Bertolotti's Syndrome Cohort
- History of spinal deformity, previous spinal surgeries, spinal infections
- Pregnant women
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Bertolotti's Syndrome
Subjects with Bertolotti's Syndrome.
|
|
Non-Bertolotti's Lower Back Pain
Subjects without Bertolotti's Syndrome with lower back pain.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To identify Bertolotti's Syndrome-specific kinematic biomarkers using collected patient kinematic and real-time VAS data from range-of-motion tasks.
Time Frame: 2025
|
2025
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michael Steinmetz, MD, The Cleveland Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB 22-1310
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.